Literature DB >> 11597989

Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis.

H C Lowe1, R G Fahmy, M M Kavurma, A Baker, C N Chesterman, L M Khachigian.   

Abstract

Early growth response factor-1 (Egr-1) controls the expression of a growing number of genes involved in the pathogenesis of atherosclerosis and postangioplasty restenosis. Egr-1 is activated by diverse proatherogenic stimuli. As such, this transcription factor represents a key molecular target in efforts to control vascular lesion formation in humans. In this study, we have generated DNAzymes targeting specific sequences in human EGR-1 mRNA. These molecules cleave in vitro transcribed EGR-1 mRNA efficiently at preselected sites, inhibit EGR-1 protein expression in human aortic smooth muscle cells, block serum-inducible cell proliferation, and abrogate cellular regrowth after mechanical injury in vitro. These DNAzymes also selectively inhibit EGR-1 expression and proliferation of porcine arterial smooth muscle cells and reduce intimal thickening after stenting pig coronary arteries in vivo. These findings demonstrate that endoluminally delivered DNAzymes targeting EGR-1 may serve as inhibitors of in-stent restenosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597989     DOI: 10.1161/hh2001.097867

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  24 in total

Review 1.  Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis.

Authors:  Florian Blaschke; Dennis Bruemmer; Ronald E Law
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 3.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

4.  c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.

Authors:  Jun Ni; Alla Waldman; Levon M Khachigian
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

Review 5.  Delivery of large biopharmaceuticals from cardiovascular stents: a review.

Authors:  Hironobu Takahashi; Didier Letourneur; David W Grainger
Journal:  Biomacromolecules       Date:  2007-10-12       Impact factor: 6.988

Review 6.  Recent developments in drug-eluting stents.

Authors:  Yue Li; Ravinay Bhindi; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

Review 7.  Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury.

Authors:  Neeta Adhikari; Nathan Charles; Ute Lehmann; Jennifer L Hall
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 8.  Early growth response-1 in the pathogenesis of cardiovascular disease.

Authors:  Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2016-06-01       Impact factor: 4.599

9.  15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Src-mediated Egr-1-dependent rapid induction of FGF-2 expression.

Authors:  Venkatesh Kundumani-Sridharan; Jixiao Niu; Dong Wang; Dong Van Quyen; Qiuhua Zhang; Nikhlesh K Singh; Jaganathan Subramani; Saradasri Karri; Gadiparthi N Rao
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

10.  Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth.

Authors:  Roger G Fahmy; Levon M Khachigian
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.